Vistagen Therapeutics, Inc. Announces Results of PALISADE-3 Phase 3 Study

Vistagen Therapeutics, Inc. announced that its PALISADE-3 Phase 3 study evaluating intranasal fasedienol for the acute treatment of social anxiety disorder did not meet its primary endpoint. The study compared the least squares mean change from baseline on the Subjective Units of Distress Scale score for fasedienol against a placebo. No significant difference in treatment effect was observed between fasedienol and placebo for the primary endpoint (fasedienol: 13.6 +/-1.54 SE vs. placebo: 14.0 +/-1.51 SE). Furthermore, no treatment difference was found for the secondary endpoints. The safety profile of fasedienol in this study was consistent with findings from previous clinical trials. The company is based in South San Francisco, California.